917396-37-3

Basic information

• Product Name: 3-Pyridinemethanol, 2-methoxy-6-(trifluoromethyl)-
• CAS NO: 917396-37-3
• Molecular Formula: C8H8F3NO2
• Molecular Weight: 207.152
• Mol File: 917396-37-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 236.0±40.0 °C(Predicted)
• Density: 1.345±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 3-Pyridinemethanol, 2-methoxy-6-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinemethanol, 2-methoxy-6-(trifluoromethyl)-(917396-37-3)
• EPA Substance Registry System: 3-Pyridinemethanol, 2-methoxy-6-(trifluoromethyl)-(917396-37-3)

Safety Data

• Hazardous Substances Data: 917396-37-3(Hazardous Substances Data)

Upstream product

• 280566-45-2 2-chloro-6-(trifluoromethyl)pyridine-3-carboxylic acid 
• 916160-41-3 2-methoxy-6-(trifluoromethyl)pyridine-3-carboxylic acid 
• 191595-63-8 2-hydroxy-6-trifluoromethylnicotinic acid 
• 917396-36-2 methyl 2-methoxy-6-(trifluoromethyl)nicotinate 

Relevant articles and documents

TRIAZOLOPYRIMIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS

The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.

Triazolopyrimidine cannabinoid receptor 1 antagonists

The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.